U.S., April 15 -- ClinicalTrials.gov registry received information related to the study (NCT07528105) titled 'Allogeneic Anti-CD7 CAR-T for Type 1 Diabetes' on April 07.
Brief Summary: Type 1 diabetes mellitus (T1DM) is a T cell-mediated autoimmune disease characterized by autoimmune destruction of pancreatic beta cells, leading to absolute insulin deficiency and lifelong dependence on exogenous insulin. The disease results from loss of immune tolerance, with autoreactive T-cell responses against beta-cell antigens, and is typically associated with islet autoantibodies and insulitis. Although insulin therapy remains the standard of care, it does not correct the underlying autoimmune process.
Non-insulin therapeutic strategies for T1DM are...